AusperBio
Latest round
- Series C
Last raised
- Aug 2026
Total raised
- $343M
Investors
- 10
About AusperBio
, trading as AusperBio, focuses on intrahepatic and extrahepatic targeted therapy. The company has acquired Med-Oligo ASO independent intellectual property rights. The company develops the Med Oligo™ small nucleic acid drug platform, hepatitis B therapeutic vaccine platform, and nasal spray antibody platform. Its R&D drug includes AHB-137, which is a naked antisense oligonucleotide (ASO). And AHB-137 can treat and prevent chronic hepatitis B and other infectious diseases. The company generates revenue by developing and commercializing oligonucleotide-based therapeutics, advancing its proprietary clinical-stage drug pipeline, and generating revenue through strategic partnerships, licensing agreements, research collaborations, and the future commercialization of treatments targeting hepatitis B, infectious diseases, cancer immunotherapy, and muscle disorders.
Who invested in AusperBio
10 investors across 5 rounds
See all investors in AusperBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AusperBio
Who invested in AusperBio?
AusperBio has 10 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AusperBio raised?
AusperBio has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did AusperBio last raise money?
AusperBio's most recent round on record is a Series C, in Aug 2026.
What does AusperBio do?
, trading as AusperBio, focuses on intrahepatic and extrahepatic targeted therapy.
Where is AusperBio headquartered?
AusperBio is headquartered in Hangzhou, China.
Which VCs invest in companies like AusperBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at AusperBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like AusperBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.